Worldwide Use of Antiretropulsive Techniques: Observations from the Clinical Research Office of the Endourological Society Ureteroscopy Global Study.
| Τίτλος | Worldwide Use of Antiretropulsive Techniques: Observations from the Clinical Research Office of the Endourological Society Ureteroscopy Global Study. |
| Publication Type | Journal Article |
| Year of Publication | 2018 |
| Authors | Saussine, C., Andonian S., Pacík D., Popiolek M., Celia A., Buchholz N., Sountoulides P., Petrut B., & de la Rosette J. J. M. C. H. |
| Journal | J Endourol |
| Volume | 32 |
| Issue | 4 |
| Pagination | 297-303 |
| Date Published | 2018 04 |
| ISSN | 1557-900X |
| Λέξεις κλειδιά | Aged, Female, Global Health, Humans, Intraoperative Complications, Kidney Calculi, Length of Stay, Lithotripsy, Male, Middle Aged, Prospective Studies, Societies, Medical, Treatment Outcome, Ureteral Calculi, Ureteroscopy |
| Abstract | INTRODUCTION: Retropulsion, defined as unintended migration of a stone under the influence of the fragmentation device in ureteroscopy (URS) procedures, occurs in 2% to 60% of the cases. Antiretropulsive devices (ARDs) have been studied in experimental and small clinical studies. The current study aims at describing the worldwide usage of ARD and the outcomes related to their usage.METHODS: The Clinical Research Office of the Endourological Society URS Global Study enrolled 11,885 patients who underwent URS and stone fragmentation for ureteral and/or renal stones. Of the 11,885 treated patients, 9877 were treated for ureteral stones, and data were available on stone migration and ARD use.RESULTS: Of all procedures, 14.5% were performed with the use of an ARD. Less stone migration (-2.0%; p = 0.050), higher stone-free rates (SFRs) (2.8%; p < 0.001), and shorter length of stay (-4.7%; p = 0.001) were observed in the antiretropulsive group.CONCLUSIONS: When an ARD is used during URS, less migration, higher SFRs, and shorter length of hospital stay are observed. This effect is independent from baseline differences and corrected for other treatment characteristics. |
| DOI | 10.1089/end.2017.0629 |
| Alternate Journal | J Endourol |
| PubMed ID | 29256629 |
